The effect on drug development of the National Cancer Institute's Cancer Therapy Evaluation Program
Zwiebel, J.
Clinical Advances in Hematology and Oncology H&o 14(3): 157-159
2016
ISSN/ISBN: 1543-0790 PMID: 27058027 Document Number: 690280
Document emailed within 1 workday
Related Documents
Schepartz, S.A. 1985: The National Cancer Institute's Drug Development Program Progress in Clinical and Biological Research 197: 73-82Kelloff, G.J.; Crowell, J.A.; Boone, C.W.; Steele, V.E.; Lubet, R.A.; Greenwald, P.; Alberts, D.S.; Covey, J.M.; Doody, L.A.; Knapp, G.G. 1994: Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute Journal of Cellular Biochemistry. Supplement 20: 55-62
Sattin, R W.; Rubin, G L.; Wingo, P A.; Webster, L A.; Ory, H W. 1987: Oral-Contraceptive Use and the Risk of Breast Cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development Obstetric and Gynecologic Survey 42(2): 120-121
Hoyt, D.B.; Holcomb, J.; Abraham, E.; Atkins, J.; Sopko, G. 2004: Working Group on Trauma Research Program summary report: National Heart Lung Blood Institute (NHLBI), National Institute of General Medical Sciences (NIGMS), and National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH), and the Department of Defense (DOD) Journal of trauma 57(2): 410-415
1987: Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development JAMA 257(6): 796-800
Kaufmann, M.; Jonat, W.; Eiermann, W.; Maass, H.; Bastert, G. 1990: Breast saving operation and adjuvant therapy of breast cancer. Report of the National Institute of Health (NIH) consensus development conference, Washington, D.C., USA, 18-21 June 1990 Onkologie 13(5): 394-396
Evans, W.K.; Coyle, D.; Gafni, A.; Walker, H. 2003: Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis Chronic diseases in Canada 24(4): 102-107
Ngo, L.S.M.; Yeo, A.; Wong, A.S.C.; Tay, M.Hiang. 2007: Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore Annals of the Academy of Medicine Singapore 36(10): 811-814
Chabner, B.A.; Curt, G.A.; Hubbard, S.M. 1984: Surgical oncology research development: the perspective of the National Cancer Institute Cancer Treatment Reports 68(6): 825-829
Schmidt, B.C. 1977: Five years into the National Cancer Program: retrospective perspectives--the National Cancer Act of 1971 Journal of the National Cancer Institute 59(2 Suppl): 687-692
Chiarodo, A. 1991: National Cancer Institute roundtable on prostate cancer: future research directions Cancer Research 51(9): 2498-2505
Ornellas, A.A.; Khouri, F.R.; Campos, F.; Koifman, N.; Quirino, R. 1999: Cancer of the urethra in women: experience of the National Institute of Cancer of Brazil: 1992-1997 Progres en urologie: journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 9(2): 292-298
Talukder, M.H.; Jabeen, S.; Shaheen, S.; Islam, M.J.; Haque, M. 2007: Pattern of cancer in young adults at National Institute of Cancer Research and Hospital (NICRH), Bangladesh Mymensingh medical journal: MMJ 16(2 Suppl): S28-S33
Shtern, F. 1998: Mobile Breast Care Center: a joint program of the Department of Defense, U.S. Public Health Service's Office on Women's Health, and the National Cancer Institute Academic Radiology 5 Suppl. 2: S409-S410
Richard, R. Brookman 1985: Rockville, MD National Institute on Drug Abuse, (ADM) 83-1152 ,Adolescent Peer Pressure. Theory, Correlates, and Program Implications for Drug Abuse Prevention (1983) Journal of Adolescent Health Care 6(1): 53-0
Ginzburg, H.M.; Glass, W.J. 1984: The role of the National Institute on Drug Abuse in the development of naltrexone Journal of Clinical Psychiatry 45(9 Pt 2): 4-6
Esik, O.; Balázs, C.; Boér, A.; Csernay, L.; Földes, J.; Füzy, M.; Horváth, O.P.; Julesz, J.; Kásler, M.; Laczi, F.; Leövey, A.; Lukács, G.; Németh, G.; Perner, F.; Repa, I.; Szabolcs, I.; Szentirmay, Z.; Trón, L.; Balázs, G. 2000: Current diagnostic method, prognosis estimation and therapy of papillary thyroid cancer: recommendations of the medical universities and the National Oncologic Institute of Budapest Orvosi Hetilap 141(1): 5-16
Haigler, H.J. 1994: The National Institute of Mental Health-Psychotherapeutic Medications Development Program (PMDP): status 1993 Psychopharmacology Bulletin 30(1): 19-22
Iwahashi, K.; Fukamauchi, F.; Aoki, J.; Kurihara, K.; Yoshihara, E.; Inoue, M.; Shibanai, H.; Ishigooka, J. 2010: A daycare program of animal assisted therapy for affective disorder patients during psychotropic drug therapy: evaluation of the relaxation effect by fNIRS (functional near-infrared spectroscopy) Nihon Shinkei Seishin Yakurigaku Zasshi 30(3): 129-134
Raju, T.N.K.; Nelson, K.B.; Ferriero, D.; Lynch, J.Kylan. 2007: Ischemic perinatal stroke: summary of a workshop sponsored by the National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke Pediatrics 120(3): 609-616